ArticlePathogens (Basel, Switzerland)2025
Comparative Efficacy of a Novel Topical Formulation with Antimicrobial Peptides and Encapsulated Plant Extracts Versus Conventional Therapies for Canine Otitis Externa.
Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Topical Anti-Inflammatory Therapies in Veterinary Medicine: Advancing Animal Health Through a One Health Approach.Animals : an open access journal from MDPI · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Canine otitis externa (OE) presents a significant challenge in veterinary medicine due to its complex, multifactorial nature and the growing issue of antimicrobial resistance (AMR) associated with conventional antibiotic use. The objective of this study was to compare the efficacy of a novel, antibiotic-free topical ear solution (Therapy A) containing antimicrobial peptides and encapsulated plant extracts (chamomile, calendula, rosemary, and hops) against a standard conventional treatment (Therapy B) composed of gentamicin, betamethasone valerate, and clotrimazole. A longitudinal, randomized study was conducted over four weeks with 40 domestic dogs diagnosed with OE. The dogs were divided into two groups, each receiving one of the therapies. Evaluations were performed weekly, assessing clinical signs using the Otitis Index Scoring System (OTIS-3) and a pruritus visual analog scale (pVAS), as well as ear canal pH and cytology. The results showed that Therapy A provided similar clinical efficacy in OTIS-3 and pVAS scores that were comparable to Therapy B. Cytological analysis also revealed a significant reduction in microbial presence for both groups. Notably, Therapy A was clinically effective in two of the three dogs presenting multi-drug resistant (MDR) bacterial infections. The novel formulation also demonstrated a favorable safety profile, with no adverse drug reactions reported, in contrast to one dog in the conventional treatment group that experienced an adverse reaction. These findings suggest that the plant-based formulation is a safe and effective alternative for managing canine OE, offering a promising solution to reduce the reliance on antibiotics and corticosteroids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.